• 1. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 2. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 3. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 4. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 5. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Benzimidazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles

Recent Advances in the Study of 1H-Benzimidazol-2-ylcyanamide (CAS: 55864-37-4): A Comprehensive Research Brief

The compound 1H-Benzimidazol-2-ylcyanamide (CAS: 55864-37-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, biological activity, and potential clinical relevance. The following sections provide a detailed overview of recent studies, highlighting key methodologies, results, and implications for future research.

Recent studies have explored the synthetic pathways for 1H-Benzimidazol-2-ylcyanamide, with particular emphasis on optimizing yield and purity. A 2023 study published in the Journal of Medicinal Chemistry demonstrated a novel, high-yield synthesis method using a one-pot reaction under mild conditions, achieving a purity of over 98%. This advancement is critical for scaling up production for preclinical and clinical studies. Additionally, the study highlighted the compound's stability under various pH conditions, suggesting its suitability for oral administration.

The biological activity of 1H-Benzimidazol-2-ylcyanamide has been a focal point of recent research. In vitro studies have revealed its potent inhibitory effects on specific kinase enzymes implicated in inflammatory pathways. For instance, a 2024 study in Bioorganic & Medicinal Chemistry Letters reported IC50 values in the nanomolar range for several kinases, positioning the compound as a promising candidate for anti-inflammatory therapeutics. Furthermore, molecular docking simulations have provided insights into its binding interactions, offering a structural basis for further optimization.

Preclinical evaluations of 1H-Benzimidazol-2-ylcyanamide have shown encouraging results in animal models of chronic inflammatory diseases. A recent study in European Journal of Pharmacology demonstrated significant reduction in pro-inflammatory cytokines and improved clinical scores in rodent models of rheumatoid arthritis. These findings underscore the compound's potential as a disease-modifying agent, though further toxicological studies are needed to assess its safety profile.

In conclusion, 1H-Benzimidazol-2-ylcyanamide (CAS: 55864-37-4) represents a promising scaffold for the development of novel therapeutics, particularly in the realm of inflammatory diseases. Recent advancements in synthesis, coupled with robust biological activity data, pave the way for future clinical trials. However, challenges such as bioavailability and long-term toxicity must be addressed to fully realize its therapeutic potential. This research brief serves as a timely update for professionals in the field, highlighting both the opportunities and hurdles associated with this compound.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)